Glycemic control for many patients with type 2 diabetes mellitus (T2DM) is elusive, and the adverse effects of treatment, including hypoglycemia and weight gain, are partially culpable. Until recently, glycosuria has been regarded only as a consequence of T2DM, but dapagliflozin employs glycosuria as a mechanism of treatment. Will this paradigm shift gain acceptance?
机构:
Univ Otago Wellington, Dept Med, Wellington, New Zealand
New Zealand Soc Study Diabet, Wellington, New ZealandUniv Otago Wellington, Dept Med, Wellington, New Zealand